Population pharmacokinetics of ethambutol in South African tuberculosis patients

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 9, 2011, Pages 4230-4237

  Jönsson, Siv ^b   Davidse, Alistair ^a   Wilkins, Justin ^a,b,c   Van Der Walt, Jan Stefan ^a,b   Simonsson, Ulrika S H ^b   Karlsson, Mats O ^b   Smith, Peter ^a   McIlleron, Helen ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b UPPSALA UNIVERSITY   (Sweden)

^c Exprimo NV   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ETHAMBUTOL; ISONIAZID; PURDERAL; PYRAZINAMIDE; RIFAFOUR; RIFAMPICIN; ROLAB; STREPTOMYCIN; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ARTICLE; BODY WEIGHT; CREATININE CLEARANCE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KIDNEY FUNCTION; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SOUTH AFRICA; STEADY STATE;

ADOLESCENT; ADULT; AGED; ANTITUBERCULAR AGENTS; ETHAMBUTOL; FEMALE; HUMANS; MALE; MIDDLE AGED; TUBERCULOSIS; YOUNG ADULT;

EID: 80051814123     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00274-11     Document Type: Article

References (39)

1. Ameer, B., R E Polk, B J Kline, and J P Grisafe. 1982. Effect of food on ethambutol absorption. Clin. Pharm. 1:156-158. (Pubitemid 12025132)
2. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America. 2003. Treatment of tuberculosis. Am. J. Respir. Crit. Care Med. 167:603-662.
3. Anderson, B J, and N H G Holford. 2009. Mechanistic basis of using body size and maturation to predict clearance in humans. Drug Metab. Pharmacokinet. 24:25-36.
4. Beal, S L, L B Sheiner, and A J Boeckmann. 1989-2006. NONMEM user's guides. Icon Development Solutions, Ellicott City, MD.
5. Bergstrand, M., A C Hooker, J E Wallin, and M O Karlsson. 2011. Prediction corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J. 13:143-151.
6. Breda, M., et al. 1999. Effect of rifabutin on ethambutol pharmacokinetics in healthy volunteers. Pharmacol. Res. 40:351-356. (Pubitemid 29472063)
7. Chideya, S., et al. 2009. Isoniazid, rifampin, ethambutol, and pyrazinamide pharmacokinetics and treatment outcomes among a predominantly HIV-infected cohort of adults with tuberculosis from Botswana. Clin. Infect. Dis. 48:1685-1694.
8. Cockcroft, D W, and M H Gault. 1976. Prediction of creatinine clearance from serum creatinine. Nephron 16:31-41.
9. Conte, J E, Jr., E. Lin, Y. Zhao, and E. Zurlinden. 2002. A high-pressure liquid chromatographic-tandem mass spectrometric method for the determination of ethambutol in human plasma, bronchoalveolar lavage fluid, and alveolar cells. J. Chromatogr. Sci. 40:113-118. (Pubitemid 35025314)
10. Donald, P R, D. Maher, J S Maritz, and S. Qazi. 2006. Ethambutol dosage for the treatment of children: Literature review and recommendations. Int. J. Tuberc. Lung Dis. 10:1318-1330. (Pubitemid 44929444)
11. Graham, S M, et al. 2006. Low levels of pyrazinamide and ethambutol in children with tuberculosis and impact of age, nutritional status, and human immunodeficiency virus infection. Antimicrob. Agents Chemother. 50:407-413. (Pubitemid 43190946)
12. Holford, N. 2005. The visual predictive check - superiority to standard diagnostic (Rorschach) plots, abstr. 738. Abstr. Population Approach Group in Europe 14. http://www.page-meeting.org/?abstract=738.
13. Israili, Z H, C M Rogers, and H. El-Attar. 1987. Pharmacokinetics of antituberculosis drugs in patients. J. Clin. Pharmacol. 27:78-83. (Pubitemid 18049894)
14. Jonsson, E N, and M O Karlsson. 1999. Xpose - an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comput. Methods Programs Biomed. 58:51-64. (Pubitemid 29049052)
15. Karlsson, M O, and L B Sheiner. 1993. The importance of modeling interoccasion variability in population pharmacokinetic analyses. J. Pharmacokinet. Biopharm. 21:735-750. (Pubitemid 24052760)
16. Karlsson, M O, and N. Holford. 2008. A tutorial on visual predictive checks, abstr 1434. Abstr. Population Approach Group in Europe 17. http://www.page-meeting.org/?abstract=1434.
17. Launay-Vacher, V., H. Izzedine, and G. Deray. 2005. Pharmacokinetic considerations in the treatment of tuberculosis in patients with renal failure. Clin. Pharmacokinet. 44:221-235. (Pubitemid 40477786)
18. Lee, C S, J G Gambertoglio, D C Brater, and L Z Benet. 1977. Kinetics of oral ethambutol in the normal subject. Clin. Pharmacol. Ther. 22:615-621. (Pubitemid 8225579)
19. Lee, C S, D C Brater, J G Gambertoglio, and L Z Benet. 1980. Disposition of ethambutol in man. J. Pharmacokinet. Biopharm. 8:335-346.
20. Lindbom, L., J. Ribbing, and E N Jonsson. 2004. Perl-speaks-NONMEM (PsN) - a Perl module for NONMEM related programming. Comput. Methods Programs Biomed. 75:85-94. (Pubitemid 38798039)
21. Lindbom, L., P. Pihlgren, and E N Jonsson. 2005. PsN-Toolkit - a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM. Comput. Methods Programs Biomed. 79:241-257. (Pubitemid 41196689)
22. McIlleron, H., et al. 2006. Determinants of rifampin, isoniazid, pyrazinamide, and ethambutol pharmacokinetics in a cohort of tuberculosis patients. Antimicrob. Agents Chemother. 50:1170-1177.
23. Murry, D J, L. Riva, and D G Poplack. 1998. Impact of nutrition on pharmacokinetics of anti-neoplastic agents. Int. J. Cancer Suppl. 11:48-51.
24. Oshikoya K A, H M Sammons, and I. Choonara. 2010. A systematic review of pharmacokinetics studies in children with protein-energy malnutrition. Eur. J. Clin. Pharmacol. 66:1025-1035.
25. Peets, E A, W M Sweeney, V A Place, and D A Buyske. 1965. The absorption, excretion, and metabolic fate of ethambutol in man. Am. Rev. Respir. Dis. 91:51-58.
26. Peloquin, C A, et al. 1996. Low antituberculosis drug concentrations in patients with AIDS. Ann. Pharmacother. 30:919-925. (Pubitemid 26295240)
27. Peloquin, C A, et al. 1999. Pharmacokinetics of ethambutol under fasting conditions, with food, and with antacids. Antimicrob. Agents Chemother. 43:568-572. (Pubitemid 29109520)
28. Perlman, D C, et al. 2005. The clinical pharmacokinetics of rifampin and ethambutol in HIV-infected persons with tuberculosis. Clin. Infect. Dis. 41:1638-1647. (Pubitemid 41691604)
29. Ramachandran, G., A K Kumar, and S. Swaminathan. 2011. Pharmacokinetics of anti-tuberculosis drugs in children. Indian J. Pediatr. 78:435-442.
30. Ruslami, R., et al. 2010. Pharmacokinetics of antituberculosis drugs in pulmonary tuberculosis patients with type 2 diabetes. Antimicrob. Agents Chemother. 54:1068-1074.
31. Savic, R M, D M Jonker, T. Kerbusch, and M O Karlsson. 2007. Implementation of a transit compartment model for describing drug absorption in pharmacokinetic studies. J. Pharmacokinet. Pharmacodyn. 34:711-726. (Pubitemid 47477040)
32. Savic, R M, and M O Karlsson. 2009. Importance of shrinkage in empirical Bayes estimates for diagnostics: Problems and solutions. AAPS J. 11:558-569.
33. Varughese, A., D C Brater, L Z Benet, and C S Lee. 1986. Ethambutol kinetics in patients with impaired renal function. Am. Rev. Respir. Dis. 134:34-38. (Pubitemid 16057456)
34. West, G B, J H Brown, and B J Enquist. 1997. A general model for the origin of allometric scaling laws in biology. Science 276:122-126. (Pubitemid 27161259)
35. West, G B, J H Brown, and B J Enquist. 1999. The fourth dimension of life: Fractal geometry and allometric scaling of organisms. Science 284:1677-1679. (Pubitemid 29291379)
36. Wilkins, J J, et al. 2008. Population pharmacokinetics of rifampin in pulmonary tuberculosis patients, including a semimechanistic model to describe variable absorption. Antimicrob. Agents Chemother. 52:2138-2148. (Pubitemid 351758551)
37. World Health Organization. 2006. Ethambutol efficacy and toxicity: literature review and recommendations for daily and intermittent dosage in children. World Health Organization, Geneva, Switzerland.
38. World Health Organization. 2010. Treatment of tuberculosis: guidelines, 4th ed. World Health Organization, Geneva, Switzerland.
39. Zhu, M., et al. 2004. Pharmacokinetics of ethambutol in children and adults with tuberculosis. Int. J. Tuberc. Lung Dis. 8:1360-1367. (Pubitemid 39611583)